The company is so far trading up by 4.41% since yesterday’s close of 8.16 and is one of the top gainers in today’s market. 65,517 shares have changed hands.
Shares are trading at $8.52 a bit higher than the 50 day moving average which is $8.22 and quite a bit above the 200 day moving average of $6.48. The 50 day moving average went up $0.30 or +3.59% and the 200 day average went up $2.04 or +31.44%.
Traders are feeling more bullish on shares of uniQure N.V. – Ordinary Shares as implied by the decrease in short interest. The stock saw a fall in short interest of -4.87% as of the latest report on August 31, 2017. Short shares decreased 45,450 over that period. The short-interest ratio increased to 12.0 and the short interest percentage is 0.03% as of August 31.
These funds have shifted positions in (QURE). Ubs Group Ag cut its position by selling 5,126 shares a decrease of 94.9% in the quarter. Ubs Group Ag currently owns 274 shares worth $2,000. The value of the position overall is down by 93.5%. Ft Options LLC divested its ownership by shedding 16,000 shares a decrease of 80.0%. Ft Options LLC owns 4,000 shares with a value of $1,000. The total value of its holdings decreased 93.3%.
As of quarter end Nantahala Capital Management, LLC had acquired a total of 707,483 shares growing its position 176.9%. The value of the investment in (QURE) increased from $2,312,000 to $6,855,000 increasing 196.5% for the reporting period. As of the end of the quarter Spark Investment Management LLC had sold 47,100 shares trimming its stake by 15.3%. The value of the company’s investment in uniQure N.V. – Ordinary Shares went from $1,775,000 to $1,610,000 a change of 9.3% since the last quarter.
As of the last earnings report the EPS was $-2.82 and is expected to be $-3.03 for the current year with 25,560,000 shares currently outstanding. Analysts expect next quarter’s EPS to be $-0.66 and the next full year EPS is projected to be $-2.60.
uniQure N.V. (uniQure) is a gene therapy company. The Company is involved in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company?s product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington’s disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington’s disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure..